DreamCIS, Inc. (KOSDAQ:223250)
South Korea · Delayed Price · Currency is KRW 6,400.00
+140.00 (2.24%)
At close: Jan 28, 2026
DreamCIS Revenue
DreamCIS had revenue of 16.52B KRW in the quarter ending September 30, 2025, a decrease of -9.22%. This brings the company's revenue in the last twelve months to 62.06B, up 9.11% year-over-year. In the year 2024, DreamCIS had annual revenue of 58.65B with 22.59% growth.
Revenue (ttm)
62.06B
Revenue Growth
+9.11%
P/S Ratio
2.42
Revenue / Employee
159.14M
Employees
390
Market Cap
150.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 58.65B | 10.81B | 22.59% |
| Dec 31, 2023 | 47.84B | 8.97B | 23.08% |
| Dec 31, 2022 | 38.87B | 12.72B | 48.64% |
| Dec 31, 2021 | 26.15B | 2.66B | 11.34% |
| Dec 31, 2020 | 23.49B | 1.38B | 6.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LabGenomics | 89.36B |
| HLB bioStep | 71.47B |
| C&R Research | 63.97B |
| DT&CRO CO. | 44.36B |
| WOOJUNG BIO | 37.12B |
| P&K Skin Research Center | 22.13B |
| BioInfra | 21.92B |
| Hyundai ADM Bio | 9.74B |